Physician profile
Michael Bruce Loggan
NPI 1336128552
$4,957.72
in general payments reported to CMS, 2019-2025
26 companies · $802 in 2025
The $802 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,136 · 2020: $349 · 2021: $483 · 2022: $605 · 2023: $762 · 2024: $821 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,385.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,833.72 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,049.90 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Glaxosmithkline, LLC. | $730.44 | 2019-2025 | Nucala |
| Mylan Specialty L.P. | $202.04 | 2019-2024 | Yupelri, Yupelri |
| Grifols USA, LLC | $166.15 | 2019-2024 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $158.17 | 2024-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $121.22 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $85.72 | 2019 | |
| Genentech USA, INC. | $74.28 | 2019-2025 | Xolair |
| Insmed, INC. | $54.93 | 2020-2024 | Arikayce |
| Harmony Biosciences LLC | $50.64 | 2020-2021 | |
| Electromed, INC. | $43.79 | 2021-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $43.71 | 2019-2023 | |
| Pulmonx Corporation | $42.90 | 2022 | |
| Amgen INC. | $37.41 | 2022-2023 | Tavneos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $35.24 | 2025 | Yupelri |
| Genzyme Corporation | $30.70 | 2025 | |
| Philips North America LLC | $29.23 | 2023 | |
| Pfizer INC. | $28.11 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $27.30 | 2022-2023 | Opsumit, Uptravi |
| Vapotherm INC | $27.21 | 2019 | |
| Baxter Healthcare | $21.85 | 2025 | Hillrom - Vest System Model 205 Acute Care |
| Paratek Pharmaceuticals, INC. | $21.56 | 2023 | Nuzyra |
| Apria Healthcare LLC | $15.79 | 2021 | |
| Verona Pharma, INC. | $13.77 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Loggan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.